Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Liabilities and Shareholders Equity (2016 - 2025)

Spero Therapeutics' Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $68.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 37.65% year-over-year to $68.9 million; the TTM value through Dec 2025 reached $262.9 million, down 53.32%, while the annual FY2025 figure was $68.9 million, 37.65% down from the prior year.
  • Liabilities and Shareholders Equity reached $68.9 million in Q4 2025 per SPRO's latest filing, up from $54.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $182.4 million in Q4 2023 to a low of $54.2 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $115.2 million, with a median of $116.1 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 66.11% in 2023, then crashed 59.92% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $171.1 million in 2021, then decreased by 27.05% to $124.8 million in 2022, then skyrocketed by 46.14% to $182.4 million in 2023, then crashed by 39.39% to $110.5 million in 2024, then plummeted by 37.65% to $68.9 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Liabilities and Shareholders Equity are $68.9 million (Q4 2025), $54.2 million (Q3 2025), and $62.1 million (Q2 2025).